CVS Health Aktie News

US stocks have been in a sharp uptrend over the past seven months, with the benchmark S&P 500 index currently up more than 35% versus its year-to-date low in April. Still, a handful of outperformers are trading at relatively low forward valuations heading into 2026.

All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1 All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1

Ubisoft Entertainment (OTCPK:UBSFY) surged nearly 9% after Tencent invested €1.16B in its Vantage Studios, boosting transformation and reducing debt. Tencent (OTCPK:TCEHY) now holds a 26.32% economic interest in Vantage Studios, while Ubisoft retains exclusive control and consolidation.

WOONSOCKET, R.I. , Nov. 20, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that its Board of Directors has elected President and Chief Executive Officer David Joyner as Chair of the Board, effective January 1, 2026.

WOONSOCKET, R.I. , Nov. 20, 2025 /PRNewswire/ -- CVS Pharmacy® today announced the launch of Joyward™, a new line of decor, gifts and more to celebrate the joy of every season.

Embedded assistant revolutionizes how members navigate their health care journey WOONSOCKET, R.I. , Nov. 18, 2025 /PRNewswire/ -- Aetna, a CVS Health® company (NYSE: CVS), is launching a market-leading generative AI-powered conversational experience in its digital channels that will simplify health care, allowing members to quickly and easily navigate their benefits for a personalized experience.

Shares in CVS Group (AIM:CVSG) nudged less than 1% higher after the veterinary services company said trading was in line with expectations, with early-year momentum holding up despite a tougher backdrop in the UK. At its annual meeting, the group reported sales up 5.7% in the four months to the end of October and a 6.2% rise in adjusted earnings.

CVS Health is successfully navigating industrywide and company-specific headwinds while maintaining a solid dividend program. Johnson & Johnson's rock-solid balance sheet and ability to develop brand-new products make its 62-year dividend growth streak safe.